We therefore consider the use of cyclooxygenase-2 inhibitors for induction of apoptosis via down-regulation of dual targets of OPN and Mcl-1 as a promising strategy in the treatment of GIST, especially in imatinib-resistant GIST; further in vitro and in vivo studies are undergoing. The gene discussed is MCL1; the disease is gastrointestinal stromal tumor.